| 28.65 -1.65 (-5.45%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.01 |
1-year : | 37.91 |
| Resists | First : | 29.98 |
Second : | 32.45 |
| Pivot price | 29.09  |
|||
| Supports | First : | 25.96 |
Second : | 21.6 |
| MAs | MA(5) : | 30.37 |
MA(20) : | 28.8 |
| MA(100) : | 29.02 |
MA(250) : | 26.37 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 68.1 |
D(3) : | 78 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 39.7 | Low : | 13.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ASMB ] has closed above bottom band by 43.6%. Bollinger Bands are 49.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 30.02 - 30.18 | 30.18 - 30.32 |
| Low: | 28.13 - 28.33 | 28.33 - 28.49 |
| Close: | 28.35 - 28.65 | 28.65 - 28.91 |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Thu, 14 May 2026
Assembly Biosciences, Inc. - Common Stock (NQ: ASMB - FinancialContent
Thu, 14 May 2026
ASMB Stock Price, Quote & Chart | ASSEMBLY BIOSCIENCES INC (NASDAQ:ASMB) - ChartMill
Wed, 13 May 2026
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts - Yahoo Finance
Wed, 13 May 2026
Oral hepatitis D entry inhibitor brings Phase 1a data to Barcelona - Stock Titan
Mon, 11 May 2026
Paradigm entities and Dr. Asefaw report holdings in Assembly Biosciences (ASMB) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 32.3 (%) |
| Held by Institutions | 59.8 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,520 (K) |
| EPS | -0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.03 |
| Profit Margin | -8.5 % |
| Operating Margin | 46.6 % |
| Return on Assets (ttm) | -4.1 % |
| Return on Equity (ttm) | -5.1 % |
| Qtrly Rev. Growth | 477.2 % |
| Gross Profit (p.s.) | 0.47 |
| Sales Per Share | 4.55 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -52.1 |
| PEG Ratio | 0 |
| Price to Book value | 2.19 |
| Price to Sales | 6.29 |
| Price to Cash Flow | -11.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|